Hyperhomocysteinemia Cell Models for Research

Hyperhomocysteinemia is a condition characterized by elevated plasma homocysteine levels, typically above 15 µmol/L. It is a significant risk factor for cardiovascular diseases, stroke, and cognitive decline. The global prevalence of hyperhomocysteinemia is estimated at 5-10% in the general population, but can be higher in elderly and in populations with folate deficiency. According to the World Health Organization (WHO), cardiovascular diseases remain the leading cause of death globally, with hyperhomocysteinemia contributing to the risk. The clinical impact includes increased risk of thrombosis, atherosclerosis, and pregnancy complications. The 5-year survival for patients with cardiovascular events is significantly reduced, with a high burden of morbidity.

Hyperhomocysteinemia is an ideal model for studying metabolic pathways, enzyme deficiencies, and gene-environment interactions. The condition has well-defined genetic determinants, such as mutations in MTHFR, CBS, and MTR genes, which can be precisely modeled using gene editing. Public datasets, including the 1000 Genomes Project and ClinVar, provide extensive genetic variation data. Open questions include the exact mechanisms by which homocysteine induces endothelial dysfunction and the role of epigenetic modifications. Gene-edited cell models allow researchers to dissect these pathways in a controlled environment, making it a valuable research area.

Hyperhomocysteinemia arises from disruptions in homocysteine metabolism, which involves two main pathways: remethylation and transsulfuration.

1. Remethylation pathway: Homocysteine is converted back to methionine by methionine synthase (MTR) with vitamin B12 as a cofactor, or by betaine-homocysteine methyltransferase (BHMT) in the liver. This pathway requires folate and vitamin B12.

2. Transsulfuration pathway: Homocysteine is converted to cystathionine by cystathionine beta-synthase (CBS) with vitamin B6 as a cofactor, ultimately producing cysteine and glutathione.

Deficiencies in enzymes (e.g., MTHFR, CBS, MTR) or nutritional deficiencies (folate, B12, B6) lead to elevated homocysteine. Elevated homocysteine causes oxidative stress, endoplasmic reticulum stress, and endothelial dysfunction, contributing to vascular damage.

Data from ClinVar and population studies.

Elevated homocysteine affects multiple signaling pathways:

• • Oxidative stress pathway: Homocysteine auto-oxidation generates reactive oxygen species (ROS), leading to lipid peroxidation and DNA damage.
• • Endothelial nitric oxide synthase (eNOS) pathway: Homocysteine inhibits eNOS activity, reducing nitric oxide production and causing endothelial dysfunction.
• • Unfolded protein response (UPR): Homocysteine induces ER stress, activating PERK, IRE1, and ATF6 pathways.
• • Inflammatory pathways: Homocysteine upregulates NF-κB, leading to increased expression of adhesion molecules (VCAM-1, ICAM-1) and pro-inflammatory cytokines.
• • Epigenetic modifications: Homocysteine affects DNA methylation by altering S-adenosylmethionine (SAM) levels, influencing gene expression.

Organoids derived from patient tissues can recapitulate tissue-specific metabolism and are useful for studying homocysteine effects in a 3D context.

• • Cbs-/- mice: Knockout mice for cystathionine beta-synthase, exhibiting severe hyperhomocysteinemia and vascular abnormalities.
• • Mthfr-/- mice: Knockout mice for methylenetetrahydrofolate reductase, showing mild hyperhomocysteinemia and developmental defects.
• • Diet-induced models: Mice fed a high-methionine or low-folate diet to induce hyperhomocysteinemia.
• • PDX models: Patient-derived xenografts for studying tumor biology in the context of hyperhomocysteinemia, though less common.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications to study hyperhomocysteinemia. Examples include:

• • MTHFR knockout cell lines: Generated in HepG2 or HUVEC backgrounds to model severe enzyme deficiency.
• • MTHFR C677T knock-in cell lines: Introduce the common thermolabile variant to study its impact on enzyme activity and homocysteine levels.
• • CBS knockout cell lines: Model classic homocystinuria.
• • MTR knockout cell lines: Study the remethylation pathway.

These gene-edited models are sequence-verified and can be used for drug screening, pathway analysis, and target validation. Commercially available, they accelerate research by providing consistent and reproducible models.

Gene-edited cell lines allow researchers to validate the function of genes involved in homocysteine metabolism. For example, MTHFR knockout cells can be used to study the effects of reduced enzyme activity on DNA methylation and gene expression. Knock-in of the C677T variant can help determine its impact on enzyme thermostability and homocysteine levels. These models are essential for understanding genotype-phenotype correlations.

Isogenic cell line pairs (e.g., wild-type vs. MTHFR knockout) are powerful tools for drug screening. They can be used to identify compounds that lower homocysteine levels or mitigate its toxic effects. For example, screening for compounds that upregulate CBS expression or activity in CBS knockout cells could identify potential therapies. Additionally, gene-edited cells can be used to study drug resistance mechanisms, such as resistance to antifolate drugs in cancer cells with MTHFR mutations.

CRISPR-based synthetic lethality screens can identify genes that are essential in the context of hyperhomocysteinemia. For instance, in MTHFR knockout cells, genes involved in alternative homocysteine metabolism or DNA repair may become essential. Such screens can reveal novel therapeutic targets and biomarkers for early diagnosis.